This enhanced therapeutic effect against APL cells correlated with the observation that ATRA treatment specifically enhanced the number and signal intensity of PML-NBs in NB4 cells (Fig. 1d and Supplementary Fig. 1). This evidence concerns the gene PML and acute promyelocytic leukemia.